Ember LifeSciences, Inc. announced that it has received $27 million in funding from Cardinal Health, Inc., Carrier Ventures, Sea Court Capital, Amgen Ventures, TDF Ventures LLC
Published on 05/27/2026
at 03:47 pm EDT - Modified on 05/26/2026
On May 27, 2026, Ember LifeSciences, Inc. has closed the transaction. The company has received $10,500,000 in its second and final tranche from new investor, Amgen Ventures and TDF Ventures LLC bringing total amount raised in the transaction so far to be $27,000,000.
Cardinal Health, Inc. is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows:
- distribution of pharmaceutical products (91.9%);
- distribution of medical, surgical and laboratory products (5.7%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic products, products of aspiration and collection of liquids, radiology intervention, respiratory assistance, etc.) ;
- other (2.4%).
The United States accounts for 99.3% of net sales.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Ember LifeSciences, Inc. announced that it has received $27 million in funding from Cardinal Health, Inc., Carrier Ventures, Sea Court Capital, Amgen Ventures, TDF Ventures LLC
Choose MarketScreener 
